Tumor resistance to vascular disrupting agents: Mechanisms, imaging, and solutions

Oncotarget

Volumn 7, Issue 13, 2016, Pages 15444-15459

  Liang, Wenjie ^a   Ni, Yicheng ^b   Chen, Feng ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Imaging; Resistance; Solutions; Vascular disrupting agents

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IODINE 131; TUMOR MARKER; VASCULAR TARGETING AGENT;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOLOGICAL MONITORING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHEMORADIOTHERAPY; ENDOTHELIAL PROGENITOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; HYPOXEMIA; ISOTOPE LABELING; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RADIOIMMUNOTHERAPY; SEQUENTIAL DUAL TARGETING INTERNAL RADIOTHERAPY; SOLID TUMOR; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; TUMOR VASCULARIZATION; ANIMAL; DIAGNOSTIC IMAGING; DRUG RESISTANCE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84971606511     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6999     Document Type: Article

References (119)

1. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 2009; 6:395-404.
2. Denekamp J, Hobson B. Endothelial-cell proliferation in experimental tumours. Br J Cancer. 1982; 46:711-20.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1:27-31.
4. Blagosklonny MV. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer biology & therapy. 2005; 4:1307-10.
5. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5:13-7.
6. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005; 5:423-35.
7. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001; 61:6413-22.
8. Taylor M, Billiot F, Marty V, Rouffiac V, Cohen P, Tournay E, Opolon P, Louache F, Vassal G, Laplace-Builhe C, Vielh P, Soria JC, Farace F. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer discovery. 2012; 2:434-49.
9. Wu XY, Ma W, Gurung K, Guo CH. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy. Journal of the Formosan Medical Association = Taiwan yi zhi. 2013; 112:115-24.
10. Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys. 1998; 42:895-8.
11. El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, Pedley RB. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer. 2005; 41:799-806.
12. Chen F, Feng Y, Zheng K, De Keyzer F, Li J, Cona MM, Wang H, Jiang Y, Yu J, Marchal G, Verfaillie C, De Geest B, Oyen R, Ni Y. Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI. PLoS One. 2012; 7: e41140.
13. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003; 9:677-84.
14. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, Chaplin DJ, Edvardsen K. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer. 2004; 111:604-10.
15. Boehle AS, Sipos B, Kliche U, Kalthoff H, Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. The Annals of thoracic surgery. 2001; 71:1657-65.
16. Brasch RC, Li KC, Husband JE, Keogan MT, Neeman M, Padhani AR, Shames D, Turetschek K. In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol. 2000; 7:812-23.
17. Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). International journal of oncology. 2001; 19:257-62.
18. Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, Montironi R, Muzzonigro G. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. International journal of immunopathology and pharmacology. 2008; 21:447-55.
19. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. Journal of cellular biochemistry. 2009; 107:1053-62.
20. Schelter F, Gerg M, Halbgewachs B, Schaten S, Gorlach A, Schrotzlmair F, Kruger A. Identification of a survival-independent metastasis-enhancing role of hypoxia-inducible factor-1alpha with a hypoxia-tolerant tumor cell line. The Journal of biological chemistry. 2010; 285:26182-9.
21. Arvidsson Y, Bergstrom A, Arvidsson L, Kristiansson E, Ahlman H, Nilsson O. Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocrine-related cancer. 2010; 17:303-16.
22. Cronin PA, Wang JH, Redmond HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer. 2010; 10:225.
23. Guo M, Cai C, Zhao G, Qiu X, Zhao H, Ma Q, Tian L, Li X, Hu Y, Liao B, Ma B, Fan Q. Hypoxia promotes migration and induces CXCR4 expression via HIF-1alpha activation in human osteosarcoma. PLoS One. 2014; 9: e90518.
24. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. The Journal of clinical investigation. 2011; 121:1969-73.
25. Squadrito ML, De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Molecular aspects of medicine. 2011; 32:123-45.
26. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007; 67:5064-6.
27. + T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 2005; 65:11752-61.
28. Wallace A, LaRosa DF, Kapoor V, Sun J, Cheng G, Jassar A, Blouin A, Ching LM, Albelda SM. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res. 2007; 67:7011-9.
29. Werner N, Nickenig G. Endothelial progenitor cells in health and atherosclerotic disease. Annals of medicine. 2007; 39:82-90.
30. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science (New York, NY). 2008; 319:195-8.
31. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. Journal of cellular and molecular medicine. 2004; 8:294-300.
32. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006; 313:1785-7.
33. Farace F, Massard C, Borghi E, Bidart JM, Soria JC. Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO. 2007; 18:1421-2.
34. Madlambayan GJ, Butler JM, Hosaka K, Jorgensen M, Fu D, Guthrie SM, Shenoy AK, Brank A, Russell KJ, Otero J, Siemann DW, Scott EW, Cogle CR. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood. 2009; 114:4310-9.
35. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008; 14:263-73.
36. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002; 109:625-37.
37. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008; 13:206-20.
38. De Palma M, Nucera S. Circulating endothelial progenitors and tumor resistance to vascular-targeting therapies. Cancer discovery. 2012; 2:395-7.
39. Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala S, Alitalo K, Weissman IL, Salven P. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A. 2008; 105:6620-5.
40. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, Schaper W. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circulation research. 2004; 94:230-8.
41. Gothert JR, Gustin SE, van Eekelen JA, Schmidt U, Hall MA, Jane SM, Green AR, Gottgens B, Izon DJ, Begley CG. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood. 2004; 104:1769-77.
42. Dignat-George F, Sabatier F, Blann A, Woywodt A. Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? J Clin Oncol. 2007; 25: e1-2; author reply e3-5.
43. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005; 11:3514-22.
44. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol. 2006; 24:1491-8.
45. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO. 2004; 15:139-45.
46. Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, Sampol J, Solovey A, Dignat-George F. Circulating endothelial cells. Biomarker of vascular disease. Thrombosis and haemostasis. 2005; 93:228-35.
47. Bhatt RS, Seth P, Sukhatme VP. Biomarkers for monitoring antiangiogenic therapy. Clin Cancer Res. 2007; 13:777s-80s.
48. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood. 2005; 106:1525-31.
49. Chen F, De Keyzer F, Ni Y: Cancer Models-Multiparametric Applications of Clinical MRI in Rodent Hepatic Tumor Model. In vivo MR Imaging: Methods and Protocols. Edited by Schroeder L, Faber C. Berlin: Humana Press (part of the Springer publishing group), 2011. pp. 489-507.
50. Loffroy R, Chevallier O, Moulin M, Favelier S, Genson P-Y, Pottecher P, Crehange G, Cochet A, Cormier L. Current role of multiparametric magnetic resonance imaging for prostate cancer. Quantitative Imaging in Medicine and Surgery. 2015; 5:754-64.
51. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, Verbeken EK, Bosmans H, Marchal G, Hermans R. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology. 2005; 234:756-64.
52. Chilla GS, Tan CH, Xu C, Poh CL. Diffusion weighted magnetic resonance imaging and its recent trend-a survey. Quantitative Imaging in Medicine and Surgery. 2015; 5:407-22.
53. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, Ahmed B, Sun X, Ni Y, Bosmans H, Hermans R, van Oosterom A, Marchal G, Landuyt W. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia. 2005; 7:779-87.
54. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G, Landuyt W, Ni Y. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology. 2005; 237:492-9.
55. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, Vandecaveye V, Peeters R, Bosmans H, Hermans R, Marchal G, Ni Y. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol. 2009; 44:44-53.
56. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004; 100:2491-9.
57. Rehemtulla A. Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia. 2012; 14:1278-89.
58. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501:328-37.
59. Gerashchenko TS, Denisov EV, Litviakov NV, Zavyalova MV, Vtorushin SV, Tsyganov MM, Perelmuter VM, Cherdyntseva NV. Intratumor heterogeneity: nature and biological significance. Biochemistry Biokhimiia. 2013; 78:1201-15.
60. Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology. 2012; 264:834-43.
61. Ahn SJ, Choi SH, Kim YJ, Kim KG, Sohn CH, Han MH, Chang KH, Min HS. Histogram analysis of apparent diffusion coefficient map of standard and high B-value diffusion MR imaging in head and neck squamous cell carcinoma: a correlation study with histological grade. Acad Radiol. 2012; 19:1233-40.
62. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gebarski SS, Fan X, Tsien CI, Lawrence TS, Junck L, Rehemtulla A, Ross BD. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005; 102:16759-64.
63. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005; 102:5524-9.
64. Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, Rehemtulla A, Ross BD. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med. 2009; 15:572-6.
65. Cho N, Im SA, Park IA, Lee KH, Li M, Han W, Noh DY, Moon WK. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging. Radiology. 2014; 272:385-96.
66. Lee KC, Hall DE, Hoff BA, Moffat BA, Sharma S, Chenevert TL, Meyer CR, Leopold WR, Johnson TD, Mazurchuk RV, Rehemtulla A, Ross BD. Dynamic imaging of emerging resistance during cancer therapy. Cancer Res. 2006; 66:4687-92.
67. Clemenson C, Chargari C, Deutsch E. Combination of vascular disrupting agents and ionizing radiation. Critical reviews in oncology/hematology. 2013; 86:143-60.
68. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer research. 2008; 28:2027-31.
69. Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys. 2004; 60:1233-40.
70. Chung F, Liu J, Ching LM, Baguley BC. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer chemotherapy and pharmacology. 2008; 61:497-502.
71. Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, Taylor NJ, Stirling JJ, Lu SP, Leach MO, Rustin GJ, Judson I. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2012; 18:3428-39.
72. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res. 2002; 8:1974-83.
73. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Frontiers in oncology. 2013; 3:259.
74. Mitrus I, Sochanik A, Cichon T, Szala S. Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta biochimica Polonica. 2009; 56:161-5.
75. Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Molecular cancer therapeutics. 2009; 8:2872-81.
76. Ng QS, Mandeville H, Goh V, Alonzi R, Milner J, Carnell D, Meer K, Padhani AR, Saunders MI, Hoskin PJ. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO. 2012; 23:231-7.
77. Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res. 2009; 15:4484-92.
78. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 2001; 61:4716-22.
79. Wilczynski J, Duechler M, Czyz M. Targeting NF-kappaB and HIF-1 pathways for the treatment of cancer: part I. Archivum immunologiae et therapiae experimentalis. 2011; 59:289-99.
80. Li J, Cona MM, Chen F, Feng Y, Zhou L, Yu J, Nuyts J, de Witte P, Zhang J, Himmelreich U, Verbruggen A, Ni Y. Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models. Theranostics. 2012; 2:1010-9.
81. Li J, Cona MM, Chen F, Feng Y, Zhou L, Zhang G, Nuyts J, de Witte P, Zhang J, Yu J, Oyen R, Verbruggen A, Ni Y. Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. Theranostics. 2013; 3:127-37.
82. Li J, Sun Z, Zhang J, Shao H, Cona MM, Wang H, Marysael T, Chen F, Prinsen K, Zhou L, Huang D, Nuyts J, Yu J, Meng B, Bormans G, Fang Z, de Witte P, Li Y, Verbruggen A, Wang X, Mortelmans L, Xu K, Marchal G, Ni Y. A dual-targeting anticancer approach: soil and seed principle. Radiology. 2011; 260:799-807.
83. Song S, Xiong C, Zhou M, Lu W, Huang Q, Ku G, Zhao J, Flores LG, Jr., Ni Y, Li C. Small-animal PET of tumor damage induced by photothermal ablation with 64Cu-bis-DOTA-hypericin. J Nucl Med. 2011; 52:792-9.
84. Shao H, Zhang J, Sun Z, Chen F, Dai X, Li Y, Ni Y, Xu K. Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. Oncotarget. 2015; 6:14247-59. doi:10.18632/oncotarget.3679.
85. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 2005; 7:101-11.
86. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Current opinion in oncology. 2000; 12:564-73.
87. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307:58-62.
88. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007; 67:9337-45.
89. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood. 2005; 106:3058-61.
90. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003; 63:4342-6.
91. Giavazzi R, Bani MR, Taraboletti G. Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer metastasis reviews. 2007; 26:481-8.
92. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 2002; 99:1-6.
93. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2001; 60:155-61.
94. Wilson WR, Li AE, Cowan DS, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys. 1998; 42:905-8.
95. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiation research. 2001; 156:503-9.
96. Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, Ryan AJ, Taraboletti G, Giavazzi R. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer. 2007; 97:888-94.
97. Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Current opinion in investigational drugs (London, England :2000). 2006; 7:522-8.
98. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2007; 10:109-20.
99. Patterson DM, Rustin GJ. Vascular damaging agents. Clinical oncology (Royal College of Radiologists (Great Britain)). 2007; 19:443-56.
100. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4:71-8.
101. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Molecular cancer therapeutics. 2004; 3:977-83.
102. Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B, Taylor NJ, Stirling JJ, Sinha R, Walicke P, Leach MO, Judson I, Nathan P. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol. 2009; 19:2728-38.
103. Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer chemotherapy and pharmacology. 2007; 59:725-32.
104. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys. 1998; 42:899-903.
105. Iversen AB, Busk M, Horsman MR. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta oncologica (Stockholm, Sweden). 2013; 52:1320-6.
106. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002; 53:164-71.
107. Masunaga S, Nagasawa H, Nagata K, Suzuki M, Uto Y, Hori H, Kinashi Y, Ono K. Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells. Journal of cancer research and clinical oncology. 2007; 133:47-55.
108. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys. 2005; 62:846-53.
109. Lankester KJ, Maxwell RJ, Pedley RB, Dearling JL, Qureshi UA, El-Emir E, Hill SA, Tozer GM. Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. International journal of oncology. 2007; 30:453-60.
110. Kacerovska D, Pizinger K, Majer F, Smid F. Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract-a pilot study. Photochem Photobiol. 2008; 84:779-85.
111. Olivo M, Du HY, Bay BH. Hypericin lights up the way for the potential treatment of nasopharyngeal cancer by photodynamic therapy. Curr Clin Pharmacol. 2006; 1:217-22.
112. Olivo M, Lau W, Manivasager V, Bhuvaneswari R, Wei Z, Soo KC, Cheng C, Tan PH. Novel photodynamic diagnosis of bladder cancer: ex vivo fluorescence cytology using hypericin. Int J Oncol. 2003; 23:1501-4.
113. Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010; 63:984-90.
114. Van de Putte M, Wang H, Chen F, De Witte PA, Ni Y. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep. 2008; 19:927-32.
115. Van de Putte M, Roskams T, Vandenheede JR, Agostinis P, de Witte PA. Elucidation of the tumoritropic principle of hypericin. Br J Cancer. 2005; 92:1406-13.
116. Van de Putte M, Ni Y, De Witte PA. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncol Rep. 2008; 19:921-6.
117. Van de Putte M, Marysael T, Fonge H, Roskams T, Cona MM, Li J, Bormans G, Verbruggen A, Ni Y, de Witte PA. Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer. 2012; 131: E129-37.
118. Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM, Bormans GM. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging. 2006; 33:595-601.
119. Belhocine TZ, Prato FS. Transbilayer phospholipids molecular imaging. EJNMMI Res. 2011; 1:17.